I have been using data from PACB and I love it. There are error rate issues but with consensus reads we are getting much improved assembly compared to other platforms.
We started with one project and now we have seven genome projects using PACB data. I hear similar things from JGI, Broad, WASHU and Sanger institutes. This company has lot of potential and they already demonstrated across multiple projects. PACB is already eating Illumina, 454 and Lifetech's lunch and dinner... This is easily 15+ stock and might be a acquisition target by Illumina, Roche or Lifetech.
in 100 k bacterias project they said going to sequensce at least 1000 microorganism, but unlimate aim is 100,000 microorganism,
hence, if it $100 k per bacterial genome then minimal revenew $100 mln
and ultimate $10 bln, no wonder CEO and CFO buying stock and agreed to cut salary to $1
note that ILMN revenue is only $1 bln, profit 100 mln and its trading at market cap 6 bln
with potential reveuew $10 bln for pacb, even if it takes 2- 3 years and hence revenue per year is 5-3 bln, this stock could be 50 bagger and trading at $150 per share
Waiting for results on XL protocol and instrument...I think revenue will double based on some data and demand that I have seen...My target for April is 5+, and if they can double their profit then it might go to 16 ( ipo level)
Sentiment: Strong Buy